Focuses on developing innovative treatments for autoimmune diseases, aiming to improve patient outcomes.
Alumis Inc. is dedicated to revolutionizing patient care by pioneering targeted therapies that replace broad immunosuppression with precise treatments. As a clinical-stage biopharmaceutical company, our primary focus is on advancing two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001 and A-005. ESK-001, a second-generation inhibitor, has shown promising therapeutic efficacy in our Phase 2 trials for moderate-to-severe plaque psoriasis (PsO). Currently, ESK-001 is undergoing further Phase 2 studies for systemic lupus erythematosus (SLE) and non-infectious uveitis, with anticipated results by the end of 2024 and 2026, respectively.
Based on encouraging Phase 2 outcomes in PsO, we plan to launch multiple Phase 3 trials of ESK-001 starting in the latter half of 2024. Meanwhile, our second candidate, A-005, is designed as a central nervous system (CNS) penetrant TYK2 inhibitor targeting neuroinflammatory and neurodegenerative disorders. We initiated the Phase 1 program for A-005 in healthy volunteers in April 2024 and expect initial findings by year-end 2024.
Alumis Inc. is driven by TYK2 genetic insights indicating protective effects against multiple sclerosis, underscoring our commitment to developing innovative treatments for debilitating conditions. With a strategic focus on precision medicine and rigorous clinical development, we aim to deliver transformative therapies that imprrove outcomes and quality of life for patients worldwide.